VIVUS Inc. VVUS reported a loss of 6 cents per share in the third quarter ... In fact, so far this year, VIVUS shares have underperformed the industry. The stock declined 43.4% during the period, while the industry witnessed a gain of 3.1%.
I know very little about cheap stocks, so I called my old pal Huckleberry Ginsberg, CSA (cheap stock analyst). The following are Huck's recommendations: Vivus (VVUS-$1.19), founded in 1991, is a $125 million-revenue …
Goerie5mon
Based on fundamentals, market trends, company events and news, and other factors, equity analysts assign price targets and recommendations to buy or sell a stock. The following graph shows how a survey of multiple analysts recommend …
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on VVUS at https://www.zacks.com/ap/VVUS Keywords: Vivus, Earnings Report
Boston, Massachusetts headquartered Vertex Pharmaceuticals Inc.'s stock finished Thursday's session 2.95% lower at $127.24 with a total trading volume of 1.37 million shares. Over the last month and the previous three months, the …
* Vivus Inc - ‍total revenue, net for third quarters of 2017 and 2016, was $15.2 million and $13.4 million, respectively * VIVUS Inc - ‍Alvogen will be solely responsible for obtaining and maintaining regulatory approvals and for all sales and ...
If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com Cambridge, …
Vivus’s Qnexa, the first of three new anti-obesity drugs under FDA review this year, came before one of the agency’s advisory committees today — and it was a swing and a miss. The panel recommended against …
Dr. Jorge Plutzky, M.D.is Independent Director of the Company,since May 9, 2013. Since 1996, he has served as the Director of The Vascular Disease Prevention Program, which includes the Lipid/Prevention Clinic, in the Cardiovascular …